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Abstract
Background: A highly sensitive, rapid and cost efficient method that can detect active botulinum neurotoxin (BoNT) in
complex biological samples such as foods or serum is desired in order to 1) counter the potential bioterrorist threat 2)
enhance food safety 3) enable future pharmacokinetic studies in medical applications that utilize BoNTs.
Methodology/Principal Findings: Here we describe a botulinum neurotoxin serotype A assay with a large immuno-sorbent
surface area (BoNT/A ALISSA) that captures a low number of toxin molecules and measures their intrinsic metalloprotease
activity with a fluorogenic substrate. In direct comparison with the ‘‘gold standard’’ mouse bioassay, the ALISSA is four to
five orders of magnitudes more sensitive and considerably faster. Our method reaches attomolar sensitivities in serum, milk,
carrot juice, and in the diluent fluid used in the mouse assay. ALISSA has high specificity for the targeted type A toxin when
tested against alternative proteases including other BoNT serotypes and trypsin, and it detects the holotoxin as well as the
multi-protein complex form of BoNT/A. The assay was optimized for temperature, substrate concentration, size and volume
proportions of the immuno-sorbent matrix, enrichment and reaction times. Finally, a kinetic model is presented that is
consistent with the observed improvement in sensitivity.
Conclusions/Significance: The sensitivity, specificity, speed and simplicity of the BoNT ALISSA should make this method
attractive for diagnostic, biodefense and pharmacological applications.
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Introduction
Botulinum neurotoxins (BoNT)s are the most poisonous
substances known [1,2]. They cause the human illnesses of infant
[3–5], wound [6], foodborne [7] and iatrogenic botulism [8–11],
but are also used to treat a variety of medical conditions [12,13].
The potential abuse of BoNT in bioweapons is feared [1,14]. The
enormous potency of the toxin is reflected by its estimated human
lethal i.v. dose of only 1-2 ng/kg body weight [1,2]. Hence, the
detection of low, but nonetheless dangerous amounts of BoNT in
complex clinical specimens or foods represents an extreme
analytical challenge.
As produced by Clostridium bacteria, BoNT is present within
,300, 500 or 900-kDa protein complexes together with non-toxic
components, known as neurotoxin associated proteins (NAPs) [15–
20]. Seven structurally distinct serotypes of BoNT (A to G) have
been discovered. The neurotoxin itself is a 150-kDa zinc-binding
metalloprotease (holotoxin) that is endogenously cleaved into a
100-kDa heavy and a 50-kDa light chain that are connected by a
reducible disulphide bond [21] and by a belt-like extension of the
heavy chain that loops around the light chain [22]. The catalytic
site is located on the light chain [23]. Reduction of the chain-
bridging disulphide bond allows for chain separation and exposure
of the catalytic site, which enhances the toxin’s activity [22,24,25].
The phenomenal potency of BoNT results from its ability to
enzymatically cleave one or more of the three SNARE proteins
that are involved in fusing acetylcholine-containing synaptic
vesicles with the terminal motor neuron membrane and trigger
muscle contraction [21,26–28].
The definitive diagnosis of botulism requires the detection of
BoNTs in a clinical specimen. The most commonly used method
to accomplish this task is the live-mouse bioassay [29–31] that can
detect as little as 10 pg of BoNT holotoxin [32], and, because of its
sensitivity, simplicity and robustness, it is considered the ‘‘gold-
standard’’. Other, generally faster, methods for detecting BoNT
include various enzyme-linked immunosorbent assays (ELISAs)
[30], a cantilever-based micromechanosensor [33], protein-based
fluorescence resonance energy transfer (FRET) sensors [34],
enzyme-amplified protein micro-arrays [35], mass spectrometric
assays [36–39], immuno-PCR detection [40], and recently, a real-
time PCR-based assay that utilizes reporter DNA-filled liposomes
that bind to immobilized BoNT/A via gangliosides [41,42].
Table 1 lists detection limits and the types of samples for which
BoNT assays were demonstrated. Most assays, except for a PCR-
based one, are unable to detect less than 1 pg/mL BoNT in a
complex sample, such as a body fluid.
Here we report a simple method, termed the BoNT Assay with
a Large Immuno-sorbent Surface Area (ALISSA), that uses
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reagents. The BoNT ALISSA can detect less than 0.5 fg of the
toxin (500-kDa BoNT/A complex) in 1 mL of serum, milk, carrot
juice or gelatin phosphate (GP)-diluent within 2.5 hours. We
present a detailed protocol and explain how we optimized the
ALISSA and defined its kinetic parameters. Our assay has the
potential to significantly improve the diagnosis of botulism and
could serve to protect humans in biomedical and bio-defense
scenarios.
Results
Assay Design
BoNT/A ALISSA consists of two main steps. First, BoNT/A is
captured and enriched on a bead-based immuno-affinity matrix
and molecules that bind the matrix non-specifically are washed
away. Second, the enzymatic activity of the immobilized BoNT/A
is determined by cleavage of a specific fluorogenic substrate. Our
enrichment matrix consists of protein A-conjugated sepharose
beads to which we coupled and crosslinked polyclonal anti-BoNT/
A antibodies (Figure 1A). These immobilized antibodies capture
BoNT/A molecules with high affinity and they do not inhibit
BoNT/A’s enzymatic function. During synthesis of the bead-based
immunomatrix it was critically important to use a neutral wash
buffer after binding and crosslinking of the antibody to the protein
A beads. When an acidic wash buffer (pH 2.8) was used instead,
the antibodies were altered such that they became inactive when
exposed to nanomolar concentrations of the toxin, probably as a
result of toxin-mediated unspecific proteolytic cleavage (Figure
S1).
Our assay utilizes a fluorogenic peptide, SNAPtide (U.S. patent
6,504,006, List Biological Laboratories), which is a molecular
beacon derivative of SNAP25, the natural substrate of BoNT/A
[27,28]. SNAPtide is cleaved by BoNT/A between a fluorophore
and a quencher (a FRET pair), thereby releasing the unquenched
fluorophore (Figure 1B and Figure S2C). The SNAPtide used here
contains a conjugated fluorescein thiocarbamoyl (FITC) quenched
by a 4-(dimethylaminoazo) benzene-4-carboxyl (DABCYL)-moie-
ty. The immobilized polyclonal rabbit antibody used does not
inhibit the specific proteolytic activity of BoNT/A and exhibits
binding affinity to the light and heavy chain of BoNT/A, as
confirmed by Western blot (Figure S2A,B).
Assay Optimization
We optimized the conditions of a prototype bead-based assay to
maximize its sensitivity and specificity for one- and ten-attomolar
concentrations of toxin in 1-mL sample volumes (Figure 2).
Therefore, we repeatedly determined the assay’s sensitivity with
serial dilutions of BoNT/A in 10% fetal bovine serum (FBS), while
evaluating the effect of the following parameters: antibody-to-
protein A crosslinking conditions, wash buffers used post-cross-
linking of antibodies to beads, number of beads, toxin-antibody
binding times and temperatures, wash buffers for removal of
Table 1. Performance of existing botulinum toxin assays.
Test method Demonstrated for Sample Type Detection Limit (fg/mL) Assay Time
Cantilever-based micromechanosensor [33] Sample buffer [33]
a 4610
8 15 min.
Mass spectrometry [36–39] milk, serum, stool extract
b 320,000 ,4h r s
ELISA [30] liquid and solid foods, serum
c 60,000 6–8 hrs
ELISA-HRP [43] therapeutic preparations
d 9,000 4–6 hrs
Mouse assay [29] foods, serum, stool
e ,6,000 typically
48 hrs
Enzyme-amplified protein microarray immunoassay
[35]
blood, plasma
f 1,400 ,10 min.
Immuno-PCR [40] carbonate buffer
g 50 4–6 hrs
Liposome PCR assay [41,42] deionized water
h 0.02 6 hrs
ALISSA (this study) serum, milk, carrot juice, gelatin phosphate diluent
h 0.5 2–3 hrs
Reported for:
aBoNT type B light chain;
bBoNT complex types A-G;
cBoNT complex types A, B, E, and F;
dBoNT purified from culture supernatant of C. botulinum type A
(A7272);
eSpores and toxin of C. botulinum type A, E, and spores of Clostridium sporogenes;
ffragment of the heavy chain of BoNT type A;
gBoNT types A, B, and E noted
as ‘‘purified to apparent homogenous from different strains of C. botulinum’’;
hBoNT/A.
doi:10.1371/journal.pone.0002041.t001
Figure 1. The ALISSA principle. (A) Synthesis scheme for the
immuno-affinity matrix for BoNT-enrichment. Protein A-agarose beads
are coupled to affinity-purified anti-BoNT antibodies. Disuccinimidyl
suberate (DSS) is used to crosslink the FC domain of the antibodies to
protein A. Non-crosslinked antibodies are removed by stringent
washing. (B) Immobilized BoNT/A cleaves a quenched FRET pair,
provided in form of a fluorogenic peptide substrate, thereby releasing
the fluorophore from the quencher, which restores fluorescence.
doi:10.1371/journal.pone.0002041.g001
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concentration, SNAPtide conversion time and the effect of
temperature during the reaction. For each BoNT/A dilution,
the fluorescence intensity was plotted against the varying
parameter (Figure 2). Due to the asymptotic nature of the
resulting curves, there are no optima for several parameters.
However, by analyzing the change in signal gain as a function of a
given parameter, we identified efficient values for each parameter
for which the steepest increase in signal gain has readily been
achieved. In consequence, the assay’s performance has become
robust and predictable.
The assay was efficient and highly sensitive when 100 mL/well
SNAPtide in 1 mM-concentration was used (Figure 2A). A reaction
time of at least one hour for the conversion of the fluorogenic
SNAPtide at room temperature (25uC) was appropriate
(Figure 2B). Within limits, the signal-gain of the assay could be
enhanced by increasing the number of beads mixed with the
sample (Figure 2C) and by extending the enzyme enrichment time
(Figure 2D). The most efficient bead concentrations were between
100,000 and 120,000 beads/mL, which correspond to a bead-bed
volume of approximately 8.7–10.4 ml when left to settle. Further
increase of the bead concentration to 500,000/mL raised the
signal intensity by only another 28% (Figure 2C). Sufficient
binding of BoNT to the bead-bound antibodies requires 3 hrs at
25uC and just 1 hr at 37uC. The measured toxin activity was
diminished at 55uC (Figure 2E), most likely due to toxin
deactivation
44 as opposed to decreased antibody binding. An
increase in temperature from 25uCt o3 7 uC during the SNAPtide-
conversion reaction also improved the signal somewhat (Figure 2F),
and reliable readings were obtained for 1 hour reaction times.
Assay performance
The pre-activated toxin, obtained through short incubations
with 5 mM DTT, produced slightly higher signals when compared
to the non-pre-activated toxin (Figure 3A). However, the
subsequent reaction with the fluorogenic reporter had to be
performed in 1.25 mM DTT, in order to avoid denaturation of
the immunoaffinity matrix and because prolonged exposure to the
more concentrated reductive agent considerably inactivated the
toxin considerably (tested on bead-free toxin; data not shown).
Sensitivity. The 150-kDa BoNT/A holotoxin (from two
different commercial sources) and the 500-kDa type A toxin
complex were serially diluted and tested by BoNT/A ALISSA in
10% FBS (Figure 3A). Robust signals of several thousand relative
fluorescence units (RFU) above background were still observed for
concentrations of one attomol/L toxin in 1-mL sample volumes.
Signals for the toxin complex were always stronger than for
identical molar concentrations of holotoxin. The practical
detection limit in 10% FBS is 1 attomol/L, which corresponds
to 0.5 fg of the 500-kDa toxin complex in a 1-mL sample (Figure 2
and 3). For a comparison with other assays see Table 1. For
practical reasons, we had used diluted FBS to optimize our assay.
To test if the ALISSA can be utilized in other more relevant
complex samples, we determined the assay’s sensitivity for the
toxin complex in spiked undiluted human serum, carrot juice,
reconstituted non-fat powdered milk, fresh milk and in GP-diluent
(Figure 3B). GP-diluent is used in the mouse bioassay for BoNT
detection. Although the discernible fluorescence was less intense
than in toxin-spiked samples with 10% FBS, BoNT/A was still
detected for 1 attomol/L toxin complex, with signal intensities of
,14,800, ,14,750, ,3,100, ,2500 and ,650 RFU above
background in undiluted human serum, 50% carrot juice, GP-
diluent, non-fat milk and fresh milk, respectively. Overall, the
ALISSA signals correlated proportionally with the toxin
concentration over several orders of magnitude (Figure 3).
Specificity and kinetics. We evaluated specificity and also
compared the sensitivity and kinetics of the bead-based ALISSA to
those of the bead-free conversion of the reporter peptide. To test
the effect of non-specific agents, we used FBS samples mixed with:
1) beads conjugated to purified unspecific rabbit IgG; 2) trypsin,
because it can also cleave SNAPtide, but it cannot be enriched on
the beads; 3) BoNT complex type B; 4.) BoNT complex type E; 5)
type A toxoid, which is a non-toxic, antibody-binding
formaldehyde inactivated derivative of BoNT/A; and 6) a toxin-
free control (Figure 4A,B). The bead-based assay produced low
intensity signals with the non-specific agents (trypsin, BoNT/A
toxoid, BoNT/B and E), and only at the highest tested
concentrations (10–100 pmol/L). The bead-free reaction mixture
produced signals only with trypsin and with BoNT/A for
concentrations of 1 pmol/L or greater, and these signals were
weak. Surprisingly, in the bead-free reaction, equimolar trypsin
concentrations produced even stronger signals than the BoNT/A
complex. This was not the case in the bead-based assay. Toxin
complexes of type B and E, for which the SNAPtide substrate does
not contain specific cleavage sites, produced signals that were
nearly undetectable at the 10 and 100 picomolar concentrations.
The intensities of these type B and E signals were even lower than
the intensities of the signals obtained with the bead-based assay
(Figure 4A,B). It is noteworthy that the bead-based detection of
BoNT/A produced much higher signals, at any given toxin
concentration, than did the bead-free reaction mixture.
Discernible signals for the bead-free reaction mixture were
obtained only for BoNT/A concentrations greater than or equal
to 1 pmol/L. In contrast, strong signals were obtained with
BoNT/A at concentrations as low as 1 attomol/L the bead-based
assay used, suggesting that the bead-based assay is at least a
million-fold more sensitive than the bead-free assay. This
remarkable enhancement of the substrate cleavage reaction,
when BoNT/A was immobilized on the beads, prompted us to
determine the kinetic parameters of the SNAPtide conversion
reaction. For comparative purposes, a fixed concentration of
BoNT/A complex (100 pmol/L) was used in 1-mL sample
volumes for both the reactions with the bead-free toxin and with
the bead-immobilized toxin. At this concentration, BoNT/A was
easily detected with either method. The hydrolysis of SNAPtide by
BoNT/A obeyed Michaelis-Menten kinetics and was
characterized by a linear relationship between the reciprocal
substrate concentration and the activity of the enzyme
(Figure 4C,D). The Km of the immobilized enzyme was 3.2-fold
lower than for the free enzyme, indicating a somewhat higher
enzyme/substrate affinity. The main effect of binding of the toxin
to the beads was found in the rate of catalysis: The immobilized
BoNT/A hydrolyzed the SNAPtide substrate at a maximal
conversion rate that was 18-fold greater than that of the
free toxin. For the free (non-immobilized) and the immobilized
enzymes the corresponding values for Vmax at 25uC
were 0.7960.04 mM/min/mg and 14.4960.27 mM/min/mg,
respectively.
Comparison between BoNT/A ALISSA and the mouse
bioassay. We performed a direct comparison of the BoNT/
ALISSA with the live-mouse bioassay. Both assays used a freshly
prepared dilution series of a common stock solution of BoNT/A
toxin complex in GP-diluent and were started within a few
minutes of the same time point. The ALISSA results became
available after ,2.5 hours, while the mice were observed for the
full four days of the standardized bioassay [44,45] (Table 2). The
mouse assay was positive for the highest test concentrations of 300
Botulinum Neurotoxin Assay
PLoS ONE | www.plosone.org 3 April 2008 | Volume 3 | Issue 4 | e2041Figure 2. Optimization of the BoNT/A ALISSA in 10% fetal bovine serum. Effect of (A) SNAPtide concentration of SNAPtide after a 1 hr
reaction time, (B) SNAPtide cleavage time, (C) number of beads, (D) BoNT enrichment time, (E) temperature during BoNT/A enrichment and (F)
temperature on cleavage of the SNAPtide. The following parameters were kept constant unless when varied as indicated: BoNT/A binding and
cleavage reaction (25uC); SNAPtide concentration (1 mM); BoNT/A enrichment time and SNAPtide cleavage time (1 hr each); number of beads
(120,000).
doi:10.1371/journal.pone.0002041.g002
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botulism developed within 96 hours in three of five mice that
received one 1/100 of the mouse LD50 (0.3 pg). The mice that
received 10
24 or 10
25 LD50 remained completely asymptomatic.
BoNT/A ALISSA produced robust, clear signals throughout the
entire series of toxin dilutions. At the lowest test concentration
(0.6 fg/mL [10
25 LD50]) the ALISSA fluorescence signal was still
,3,100 units above background (Table 2).
Discussion
The BoNT/A ALISSA avoids interference with other sample
components by using a highly BoNT/A-specific affinity matrix
and by using a BoNT/A-specific substrate to exploit the natural
proteolytic activity of the toxin. Both steps also amplify the signal
by 1) localized enrichment of the toxin and 2) through enzymatic
conversion of billions of substrate molecules per toxin molecule.
The capture matrix is designed to stably enrich the toxin, while
retaining its enzymatic activity and by purifying the toxin from
other unspecific, sample-contained, proteases. Like the Endopep-
MS method [36–39], we used a beaded protein A matrix to bind
anti-BoNT/A antibodies via their FC-portions, orienting the
antibody binding domains away from the bead surface and into
the surrounding fluid, which we expected to provide high
accessibility for toxin molecules.
The plateaus seen in the assay’s response curves, used to
optimize the substrate concentration (Figure 2A) and the size and
volume proportions of the immunosorbent matrix (Figure 2C),
represent saturation effects that indicate when the substrate
concentration is no longer rate-limiting or how much antibody is
needed to capture most of the toxin molecules, respectively. We
have determined that the antibody binding capacity of the beads
was 50 mg antibody per one million beads, and therefore, we
estimated the antibody’s dissociation constant kD at half maximum
saturation to be approximately 15 nM (Figure 2C). It should be
possible to further improve the assay’s sensitivity by using
antibodies with higher binding affinities. High affinity anti-BoNT
antibodies have also been used as antitoxins to neutralize systemic
botulinum toxin in botulism patients [46,47]. It is important to
point out that this mode of ‘‘neutralization’’ should not be
confused with inactivation of the toxin’s enzymatic activity by
steric hindrance of the catalytic site as a result of antibody binding.
The antibody-mediated ‘‘neutralization’’ of the toxin in the human
body relies on the formation of an antibody-antigen complex and
its subsequent hepatic accumulation and clearance [48,49].
The use of a standard curve to measure the concentration-
dependent intensity of the fluorescence signal of an un-quenched
calibration peptide (Figure S3) enabled us to determine the molar
conversion rate for the substrate molecules. For the 10 attomolar
toxin concentration, we calculated a substrate conversion rate of
approximately two billion substrate molecules per one immobi-
lized toxin molecule per hour. The reaction is limited by the rate
at which the toxin becomes inactivated. Several factors may
contribute to the inactivation of the toxin: 1) chelation of the zinc
atom [50] by DTT, 2) denaturation of the toxin by the reducing
buffer [25], or 3) proteolytic degradation of the toxin either
through autoproteolysis [51,52] or by a contaminant protease.
The optimal temperature for the assay is 37uC (Figure 2E,F),
which coincides with the temperature at which the natural action
of the toxin occurs [53] and at which binding to the IgG antibody
appears to be optimal. Higher temperatures inactivate the toxin
[53,54]. The pH of the sample should be approximately neutral
(between 6 and 8). Further improvement of the assay’s sensitivity
may be feasible by reducing the background fluorescence of the
uncleaved SNAPtide. The FITC/DABCYL donor/acceptor pair
used in this study already exhibits some fluorescence due to a non-
optimal overlap of the FITC emission spectrum with the
absorption spectrum of DABCYL (Figure S4). A peptide-
conjugated FRET pair with a 2,4-dinitrophenyl acceptor and a
4-methyl-7-dimethylamino-coumarin donor has been described as
a substrate for BoNT/A [55]. This and other FRET pairs with a
better spectral overlap, potentially lower background fluorescence,
and good kinetic properties may be tested as fluorogenic substrates
in the future.
Our kinetic studies revealed an approximately 18-fold increase
in the maximum conversion rate vmax and a three-fold higher
affinity to the substrate (three-fold lower kM) for the immobilized
toxin than for the free toxin in solution (Figure 4C,D). Similar
Figure 3. Sensitivities of BoNT/A ALISSA. BoNT/A detection in (A) 10% fetal bovine serum (FBS) to various forms and sources of the toxin;
a Metabiologics (Madison, WI) and
b List Biological Laboratories (Campbell, CA); (B) in undiluted human serum, 50% carrot juice (with binding buffer),
gelatin phosphate diluent (GPD), reconstituted powdered milk (fat free) and fresh whole milk (2% fat). Pre-act.=toxin preactivated with 5 mM DTT; all
reactions with SNAPtide were carried out with 1.25 mM DTT.
doi:10.1371/journal.pone.0002041.g003
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immobilized enzymes, such as immobilized trypsin, and the effect
is attributed to the increased reaction surface area and the control
of diffusion through more frequent substrate-enzyme interac-
tions[56]. We have also detected a weak interaction between the
uncleaved substrate and the bead surface (Figure S5). This weak
interaction may contribute to a higher local concentration of
SNAPtide on the bead surface and a shorter time of diffusion
Figure 4. BoNT/A ALISSA versus bead-free SNAPtide cleavage. Comparison between (A, C) the bead-based assay and (B, D) the bead-free
reaction in 10% FBS. (C, D) Lineweaver-Burk (double reciprocal) plots of the BoNT/A reaction rate as a function of the substrate (SNAPtide)
concentration. Note different y-axis scales. The solid lines represent linear regression fits.
doi:10.1371/journal.pone.0002041.g004
Table 2. Comparison of the mouse bioassay with BoNT/A ALISSA.
[toxin A complex] (fg/mL) LD50s
a Mouse bioassay result ALISSA result (RFU)
300,000.0 5 5/5 dead in ,4 hrs 51,105695
60,000.0 1 5/5 dead in ,21 hrs 48,0096464
600.0 10
22 3/5 mild symptoms
b 28,04961713
6.0 10
24 5/5 disease free
b 13,95461324
0.6 10
25 5/5 disease free
b 3,116615
0.0 0 n.d. 068
a calculated per injected 0.5 mL sample; one LD50=30 pg BoNT/A complex;
b all mice alive after 96 hrs; n.d., not determined; sample medium=gelatin phosphate
diluent.
doi:10.1371/journal.pone.0002041.t002
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active site of a toxin molecule.
The average bead surface area in the ALISSA assay is
approximately 7.85 cm
2 per sample (based on a 50 mm average
bead diameter) whereas the antigen-binding surface area in a
conventional ELISA with a 96-well flat-bottom polystyrene
microplate measures only about 0.256 cm
2 per well (BD Falcon
plate, cat. #353279). The available reaction surface area in the
ALISSA is therefore about 30-fold larger than in an ELISA. In
addition, it is possible that immobilized BoNT/A is better
protected from proteolysis and aggregation. Once immobilized,
molecules of the unstable BoNT/A light chain should be
sufficiently separated from each other to diminish their autocat-
alytic degradation. The use of a bead-based assay allows for
stringent wash steps that diminish interference with other
proteases, as demonstrated for BoNT/A in comparison with
equimolar concentrations of trypsin, BoNT/B and BoNT/E.
The ALISSA performed with comparable sensitivities in
undiluted human serum, 50% carrot juice (adjusted to pH 7.5
with binding buffer), reconstituted powdered milk, fresh milk and
GP-diluent. In direct comparison with the mouse assay the
ALISSA was considerably faster and four to five orders of
magnitude more sensitively (Table 2.). A more accurate compar-
ison would require a significantly larger number of mice to obtain
a precise mouse-LD50 (MLD50). Here we used the MLD50
provided by the toxin manufacturer, and found that the value
given was largely consistent with our experimental results.
Ultimately, the BoNT ALISSA might help to reduce animal use
for the associated lethal test procedure. A rough estimate on the
economy of the assay reveals an average reagent cost of ,$15 per
sample (Table S1), which is expected to be much lower than the
costs associated with utilization of an animal facility to ensure
constant availability of live animals for diagnostic purposes.
Conclusion
The BoNT/A ALISSA is an inexpensive, simple and robust
procedure that ensures high analytical specificity and attomolar
sensitivity for the detection of BoNT/A in complex biological
samples. Future modification of our assay to encompass other
BoNT serotypes, and even other classes of toxins, should become
feasible as soon as the necessary substrate reagents become
available.
Materials and Methods
Reagents
The 150-kDa BoNT A holotoxin was purchased from List
Biological Laboratories (Campbell, CA) and from Metabiologics
Inc. (Madison, WI). The 500-kDa BoNT/A complex and the
BoNT/A toxoid were obtained from Metabiologics. All toxins
were produced by a Hall A strain of Clostridium botulinum. The
BoNT/A subtype used here is therefore A1. Toxin activities for
the holotoxin and the complex were 2.1610
8 MLD50/mg and
3.6610
7 MLD50/mg, respectively, according to Metabiologics.
The fluorogenic peptide SNAPtide (FITC/DABCYL, product
#521) and the unquenched calibration peptide, containing an N-
terminally FITC-labeled fragment of SNAPtide (product #528,
synthetic, but sequence identical to the BoNT/A cleaved product),
were from List Biological Laboratories. Affinity purified rabbit
polyclonal antibodies against Clostridium botulinum A toxoid were
from Abcam (Cambridge, MA, cat #ab20641). Purified rabbit
IgG was from ICN Pharmaceuticals, Inc. (Aurora, OH), the Seize
X Protein A immunoprecipitation kit was from Pierce (Rockford,
Il), trypsin was from Promega, and fetal bovine serum was from
Invitrogen (Carlsbad, CA). Human serum was from Sigma (cat.
#H4522) and carrot juice was from Bolthouse Farms (Organics,
100% carrot juice, 1 liter bottle). Other reagents were from Sigma
unless indicated.
Gel electrophoresis and Western Blots
Gels were analyzed by Western Blot using the same polyclonal
rabbit antibody that was used in the ALISSA. Gels bands were
visualized with the SimpyBlue SafeStain kit from Invitrogen
(Carlsbad, CA).
Preparation of the immunomatrix
Anti-BoNT/A antibodies were bound and then covalently
cross-linked to the bead-immobilized protein A molecules to
prevent them bleeding off when mixed with the sample. The
release of antibodies into the sample would otherwise lower the
sensitivity of the assay drastically. To produce such a stable
immunomatrix we used a Seize X Immunoprecipitation Kit
(Pierce, product #45215) essentially as described by the
manufacturer, but with some modifications. Briefly, 125 mgo f
anti-BoNT/A antibodies in 0.4 mL of the kit’s binding/wash
buffer (14 mM NaCl, 8 mM sodium phosphate, 2 mM potassium
phosphate and 10 mM KCl, pH 7.4) were incubated with the
protein A bead support for one hour to ensure complete binding.
Crosslinking was performed by adding 25 mL of freshly dissolved
disuccinimidyl suberate (DSS) (25 mg/mL) in DMSO to the beads
in a Handee spin cup followed by gentle mixing on a Labquake
rotisserie (Barnstead International, Dubuque, IA) for 30-60
minutes at room temperature. The beads were centrifuged and
washed three times with 500 mL ‘‘Gentle Elution buffer’’ and two
times with 500 mL ‘‘Gentle Binding’’ buffer (Pierce, product
#21030). Spin Cup columns with functionalized beads were
wrapped with parafilm and stored at 4uC until used. Bead
numbers were enumerated with a Reichert Bright-Line Metallized
Hemacytometer from Hausser Scientific (Horsham, PA).
BoNT/A assay with a large immuno-sorbent surface area
(ALISSA)
The concentrations of the substrate and the amounts of time for
BoNT/A enrichment the cleavage reaction were varied as shown
in Figure 2; the values presented here are the optimized values.
BoNT/A holotoxin or BoNT complex type A were reconstituted
(when received dry) in 20 mM HEPES, pH 8.0, 0.05% Tween-20,
0.3 mM ZnCl2, 1.0 mg/mL BSA. The toxin stock concentrations
were validated by two independent methods 1) Bicinchoninic acid
protein assay kit (Pierce) and 2) UV photometric by measuring of
the absorbance at 280 nm with a NanoDrop ND-1000 system
(Thermo Fisher). The toxin solutions were either used untreated or
pre-activated by incubating with 5 mM dithiothreitol (DTT) for
30 minutes at 37uC. Serial dilutions of BoNT/A, B, E and trypsin
in concentrations from nanomolar to subattomolar were prepared
separately in 2.0 mL tubes with either 10% fetal bovine serum
(FBS), undiluted human serum, 50% carrot juice (in ‘‘Gentle
Binding’’ buffer, pH 7.5), 3% reconstituted non-fat milk (Carna-
tion from Nestle) in Dulbecco’s phosphate buffered saline solution
(PBS) (Irvine Scientific, Santa Ana, CA), fresh milk (2% fat), or
gelatin phosphate diluent (2 g/L gelatin (Difco, cat #214340),
4 g/L dibasic sodium phosphate, pH adjusted with 1 M HCl to
6.2). For the comparison of bead-free versus bead-based assay,
toxin concentrations and total toxin amounts were identical in
each dilution step. Beads with immobilized antibodies were added
to the toxin-spiked samples and rotated at 8 rpm for 1 hour at
37uC, centrifuged at 1700 g for 10 min, and washed three times
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40 mM HEPES) was required for analyses of fresh milk samples.
The beads were resuspended in 300 mL reaction buffer (20 mM
HEPES, 0.3 mM ZnCI2, 1.25 mM DTT, 0.1% Tween-20,
pH 8.0) with 1.0 mM SNAPtide allowed to react in the dark for
1 hour at 37uC while rotating at 8 rpm. The tubes were
centrifuged and the supernatant was distributed evenly in
triplicates (100 mL/well) on a black, polystyrene, 96-well flat-
bottom microtiterplate (Fisher Scientific) and mixed with 200 mL
EDTA (20 mM). Fluorescent intensities were measured on a
Wallac 1420 Multilabel Counter Victor
2 spectrophotometer
(PerkinElmer) at excitation and emission wavelengths of 485 nm
and 535 nm, respectively.
Microscopy
Beads were mounted on glass slides and examined in phase
contrast and fluorescence modes with an Olympus BH2-RFCA
microscope (Japan).
Kinetic studies
Km and Vmax values for the reactions of BoNT/A with bead-
free or bead-immobilized SNAPtide were calculated from double
reciprocal Lineweaver–Burk plots. Eight distinct concentrations of
substrate from 0.025 to 5 mM were used. Initial velocities for the
reactions were calculated from linear regression analysis as mMo f
cleaved SNAPtide/min/mg enzyme. Values are averages of four
independent determinations.
Comparison of BoNT/A ALISSA with the mouse assay
A split aliquot of 100 ng BoNT/A toxin complex was shipped
overnight in a refrigerated hazmat container from City of Hope to
the Infant Botulism Treatment and Prevention Program of the
California Department of Public Health (CDPH) in Richmond for
use in the diagnostic live-mouse bioassay. Identical dilution series
of the toxin in GP-diluent were prepared concurrently in pre-
prepared and weighed vials at both institutions. 18-22 g mice were
injected i.p. with 0.5 mL/mouse of sample and watched for signs
of botulism or death for the standard 96 hour observation period
[44]. The start of the i.p. mouse injections at CDPH were
coordinated by telephone to coincide with the start of the ALISSA
at City of Hope within a margin of minutes. BoNT/A ALISSA
results became available after ,2.5 hours.
Supporting Information
Figure S1 The capture antibodies are altered when the beads
are washed with an acidic buffer (pH 2.8) following IgG-to-protein
A binding and crosslinking. As a result the relative fluorescence
intensity of the assay is reduced in presence of BoNT/A at
concentrations .50 pg/mL, presumably due to unspecific degra-
dation of the antibodies by the metalloprotease.
Found at: doi:10.1371/journal.pone.0002041.s001 (0.03 MB PDF)
Figure S2 (A) Reaction of the fluorogenic SNAPtide with
BoNT/A in the absence or presence of an anti-BoNT antibody
(in molar excess) in 10% FBS. (B) SDS gel bands and Western blot
of the BoNT/A complex. The Western blot was developed with
the rabbit anti-BoNT/A antibody used for ALISSA. (C)
Micrograph of a bead particle used to immobilize BoNT/A in
phase contrast (left) and under fluorescence (right) after reacting
with SNAPtide. RFU=relative fluorescence units; HC,
LC=BoNT/A heavy and light chain, respectively.
Found at: doi:10.1371/journal.pone.0002041.s002 (0.13 MB PDF)
Figure S3 Standard curve of the fluorescence signal of the
unquenched calibration peptide, which is structurally identical to
the FITC-containing cleavage product resulting from BoNT/A
hydrolysis of SNAPtide by BoNT/A; y in RFU; x in nM; R is the
correlation coefficient
Found at: doi:10.1371/journal.pone.0002041.s003 (0.03 MB PDF)
Figure S4 UV/VIS spectra of the quencher DABCYL and the
fluorophore FITC. Absorbance spectrum of DABCYL (green
dashed line), emission spectra of FITC as an fluorescein antibody
conjugate (blue line) and as a fluorescein-dextran conjugate (red
line), both at pH 8.0; adapted from the online Fluorescence
Spectra Viewer (http://probes.invitrogen.com/servlets/spectra/)
with kind permission from Dr. Iain Johnson, Invitrogen Corpo-
ration, Molecular Probes.
Found at: doi:10.1371/journal.pone.0002041.s004 (0.18 MB PDF)
Figure S5 Weak interaction of SNAPtide with protein A
sepharose beads: One mL of 50 nM SNAPtide was incubated
with 0, 70 k, 140 k and 350 k beads in the reaction buffer for 1
hour at 37uC. The supernatant was removed and treated with
trypsin, resulting in approximately 10% cleavage of SNAPtide. A
,30% reduction in the fluorescence signal is observed for 350,000
beads, which corresponds to the absorption/adsorption ratio of
,30% of the original SNAPtide and reflects a 10-fold concentra-
tion of SNAPtide within the bead volume of 30 mL.
Found at: doi:10.1371/journal.pone.0002041.s005 (0.03 MB PDF)
Table S1 ALISSA cost analysis
Found at: doi:10.1371/journal.pone.0002041.s006 (0.03MBDOC)
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